Medulloblastoma/primitive neuroectodermal tumour studied as a Matrigel enhanced subcutaneous xenograft model.
An important role for pre-clinical models of medulloblastoma/primitive neuroectodermal tumour (MB/PNET) is inhibited by the limitations of conventional heterotransplantation. Nine cohorts of MB/PNET were studied for subcutaneous engraftment in nude mice by both conventional and Matrigel supplemented methods. While no subcutaneous tumours resulted from 63 conventional attempts, an aggregate 41 xenografts from 72 injections (57%) were produced when Matrigel was added to the cell suspension. In subsequent passage, engraftment rate approached 100%. To study the response to chemotherapeutic agents in the model, a total of 221 tumours in 3 cohorts were treated using one of the following: cisplatin, carboplatin, vincristine, cyclophosphamide, diaziquone, or saline control. While all agents demonstrated statistically significant activity, cyclophosphamide proved to be particularly effective. The potential applications of this xenograft model in the biologic as well as therapeutic study of MB/PNET deserve continuing investigation.
White
L
L
Children's Cancer Institute Australia, Sydney Children's Hospital and University of NSW, Randwick, Australia.
Sterling-Levis
K
K
Kees
U R
UR
Tobias
V
V
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D001388:Aziridines / Q000494:pharmacology; D016227:Benzoquinones / Q000494:pharmacology; D001672:Biocompatible Materials; D016190:Carboplatin / Q000494:pharmacology; D002528:Cerebellar Neoplasms / Q000188:drug therapy*; D002945:Cisplatin / Q000494:pharmacology; D003094:Collagen; D003520:Cyclophosphamide / Q000494:pharmacology; D004338:Drug Combinations; D016130:Immunophenotyping; D007797:Laminin; D008527:Medulloblastoma / Q000188:drug therapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D018242:Neuroectodermal Tumors, Primitive / Q000188:drug therapy*; D011509:Proteoglycans; D016896:Treatment Outcome; D014750:Vincristine / Q000494:pharmacology; D023041:Xenograft Model Antitumor Assays / Q000379:methods*
D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D000972:Antineoplastic Agents, Phytogenic; D001388:Aziridines; D016227:Benzoquinones; D001672:Biocompatible Materials; D004338:Drug Combinations; D007797:Laminin; D011509:Proteoglycans; C059485:matrigel; D014750:Vincristine; D003520:Cyclophosphamide; D003094:Collagen; D016190:Carboplatin; C029108:diaziquone; D002945:Cisplatin